Education
Why Ozempic Doesn’t Work for Everyone: The DNA Clue
This episode explains why Ozempic and similar weight-loss drugs don’t work the same for everyone, highlighting a Stanford University study published in April 2026. Researchers found that about 10% of people carry variants in a single gene affecting the enzyme PAM, which helps activate the body’s natural GLP-1 hormone—the system these medications rely on. With a sluggish PAM “switch,” GLP-1 may not be properly activated, which could help explain why some patients lose a lot of weight while others see minimal results. The host offers three takeaways: lack of response may not be willpower-related, genetic testing may eventually guide drug choice, and non-responders should discuss alternatives like SGLT2 inhibitors with a doctor. The episode notes this is early research and no approved predictive test exists yet.
00:00 Welcome and Setup
00:20 Ozempic Works Differently
00:43 The Gene Behind Response
01:18 Why GLP-1 Drugs Vary
01:38 Three Key Takeaways
02:17 Early Research Caveats
02:40 Wrap Up and Share